{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T01:29:38Z","timestamp":1773883778194,"version":"3.50.1"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03360-y","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T12:06:19Z","timestamp":1725624379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Oral naltrexone in the treatment of lichen planopilaris and frontal fibrosing alopecia"],"prefix":"10.1007","volume":"316","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7272-206X","authenticated-orcid":false,"given":"Sofia M.","family":"Perez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0402-3926","authenticated-orcid":false,"given":"Betty","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5516-4043","authenticated-orcid":false,"given":"Antonella","family":"Tosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"issue":"6","key":"3360_CR1","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/j.jaad.2018.12.031","volume":"80","author":"B Lee","year":"2019","unstructured":"Lee B, Elston DM (2019) The uses of naltrexone in dermatologic conditions. J Am Acad Dermatol Jun 80(6):1746\u20131752. https:\/\/doi.org\/10.1016\/j.jaad.2018.12.031","journal-title":"J Am Acad Dermatol Jun"},{"issue":"2","key":"3360_CR2","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1080\/09546634.2020.1774488","volume":"33","author":"V Lajevardi","year":"2022","unstructured":"Lajevardi V, Salarvand F, Ghiasi M, Nasimi M, Taraz M (2022) The efficacy and safety of oral low dose naltrexone versus placebo in the patients with lichen planopilaris: a randomized controlled clinical trial. J Dermatolog Treat Mar 33(2):769\u2013773. https:\/\/doi.org\/10.1080\/09546634.2020.1774488","journal-title":"J Dermatolog Treat Mar"},{"issue":"6","key":"3360_CR3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.36849\/JDD.6810","volume":"1","author":"E Klein","year":"2022","unstructured":"Klein E, Karim M, Kim R, Lo Sicco K, Shapiro J (2022) Reversible hair loss in Lichen Planopilaris: Regrowth with Low-Dose Naltrexone and platelet-rich plasma. J Drugs Dermatol Jun 1(6):671\u2013673. https:\/\/doi.org\/10.36849\/JDD.6810","journal-title":"J Drugs Dermatol Jun"},{"key":"3360_CR4","doi-asserted-by":"publisher","unstructured":"Yossef SM, English JC 3 (2024) Attenuation of disease process following treatment with low-dose naltrexone in patients with frontal fibrosing alopecia and lichen planopilaris: a retrospective study. J Am Acad Dermatol Mar 19. https:\/\/doi.org\/10.1016\/j.jaad.2024.03.010","DOI":"10.1016\/j.jaad.2024.03.010"},{"issue":"1","key":"3360_CR5","doi-asserted-by":"publisher","first-page":"e34169","DOI":"10.7759\/cureus.34169","volume":"15","author":"RK Hamel","year":"2023","unstructured":"Hamel RK, Chen L, O\u2019Connell C, Mann C (2023) Oral low-dose naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: an uncontrolled open-label prospective study. Cureus Jan 15(1):e34169. https:\/\/doi.org\/10.7759\/cureus.34169","journal-title":"Cureus Jan"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03360-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03360-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03360-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T16:10:30Z","timestamp":1729699830000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03360-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":5,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["3360"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03360-y","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]},"assertion":[{"value":"20 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was reviewed and approved by the University of Miami Institutional Review Board, approval number 20220364.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"This study involved the retrospective review of medical records. There was no prospective contact with potential study subjects prior to acquisition of the requested data. As a result, a waiver of consent was obtained from the University of Miami Institutional Review Board in accordance with 45 CFR \u00a7\u00a046.116(f)(3). This research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Dr. Tosti is an investigator for Eli Lilly and Concert and a consultant for DS Laboratories, Almirall, Thirty Madison, Eli Lilly, Bristol Myers Squibb, P&G, Pfizer, Ortho Dermatologics, and Myovant. The remaining authors have no conflicts to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"605"}}